In this randomized, double-blind, parallel group, placebo-controlled, dose-ranging study, we have compared three doses (0.1 mg, 1.0 mg and 3.0 mg) of the 5-HT 3 receptor antagonist, granisetron (Kytril), as prophylactic therapy for the prevention of postoperative nausea and vomiting. The aims were to determine the optimal dose of granisetron and to evaluate its safety profile. We studied 527 adult patients, undergoing elective open abdominal surgery or vaginal hysterectomy during general anaesthesia. Antiemetic prophylaxis with a single dose of granisetron 1.0 mg or 3.0 mg resulted in a significant reduction (P : 0.001 compared with placebo) in the numbers of patients experiencing postoperative vomiting, or nausea, or who achieved total control during the postoperative periods 0-6 h and 0-24 h. The two higher doses of granisetron (1.0 mg and 3.0 mg) provided effective prophylaxis against vomiting, with 78 % and 77 % of patients, respectively, being free from vomiting in the first 6 h after surgery, and 63 % and 62 % in the first 24 h. This compares with 50 % and 34 % at 0-6 h and 0-24 h, respectively, in the placebo group. Granisetron was well tolerated and the optimum dose was 1.0 mg. (Br.
Granisetron (Kytril) is a highly selective and potent 5-HT3 receptor antagonist [1] . It is believed to act specifically at 5-HT3 receptors on the vagal afferent nerves of the gut. Studies have shown that granisetron (in contrast with ondansetron) produces irreversible block of the 5-HT3 receptor [2, 3] which may account for the long duration of action of the drug. Furthermore, in studies comparing the potency of three different 5-HT3 receptor antagonists, granisetron was shown to have a greater potency than tropisetron, which in turn had a greater potency than ondansetron [4] . Granisetron has proved to be safe and effective against nausea and vomiting induced by cancer chemotherapy when given as a single 3.0 mg dose [5] . Therefore, in this study we have determined the optimal dose of granisetron (0.1, 1.0 or 3.0 mg), given as a single i.v. injection for prevention of postoperative nausea and vomiting (PONV), and evaluated the safety profile of granisetron when given before surgery.
Patients and methods
This multinational, multicentre study was carried out in 35 centres in Denmark, Finland, France, Italy, The Netherlands, South Africa, Switzerland and the UK with the approval of the Ethics Committees in each centre. It was a randomized, double-blind, parallel group, dose-ranging study comparing three single doses of i.v. granisetron with placebo.
We studied patients of both sexes, over the legal age of consent, who were undergoing elective open cholecystectomy, open gynaecological procedures or vaginal hysterectomy during general anaesthesia. Exclusion criteria were ASA class IV or V, body weight 25 % or more above ideal, breast feeding or pregnancy, known sensitivity to 5-HT3 antagonists or if patients were already experiencing vomiting or moderate-to-severe nausea or had taken antiemetic drugs in the 24 h before surgery.
A history of susceptibility to motion sickness or past history of PONV was recorded. Among female patients, a menstrual history was also obtained, as the incidence of PONV is known to be affected by the phase of the menstrual cycle [6] .
After giving written informed consent, patients were allocated to a treatment group to receive one of the three doses of granisetron or placebo using a computer-generated randomization schedule. Granisetron or placebo was given as an i.v. injection over 30 s, 5 min before induction of anaesthesia. The study was blinded by each syringe being preloaded with the same amount of fluid but a different dose of granisetron (0, 0.1 mg, 1.0 mg or 3.0 mg), depending on the randomization code. Patients were scheduled to receive general anaesthesia with the following agents: no premedication or benzodiazepine premedication, i.v. barbiturate induction, maintenance with nitrous oxide and a volatile agent in oxygen, intraoperative opioid analgesics, neuromuscular block and antagonism of neuromuscular block as required, and postoperative analgesia with opioid or non-opioid analgesics, or both. Duration of operation and the time taken for patients to respond to verbal commands (recovery time) were also noted.
Patients were assessed by the investigators 1, 2, 6 and 24 h after operation. At each of these times, the incidence of nausea, vomiting, or both, and the patient's subjective assessment of pain were recorded. The time of onset of the first episode of nausea, vomiting, or both, was also noted. The major measures of efficacy were number of patients who did not report any nausea or vomiting 0-6 h and 0-24 h after recovery from anaesthesia. Patients who experienced nausea or vomiting, or both, such that further antiemetic treatment was deemed necessary by the attendant physician, were given rescue antiemetics (either prochlorperazine or metoclopramide) and classed as treatment failures. A patient with total control was defined as one who had no nausea, no vomiting, no rescue therapy and had not been withdrawn during the 24 h after anaesthesia.
Patients were followed up from 4 to 8 days after operation. Return of bowel function was assessed after 6 h and 24 h by recording the return of flatulence or evacuation of stool. Vital signs (heart rate, arterial pressure and temperature) were recorded. Blood samples were obtained before drug administration, at 24 h and at follow-up, for plasma creatinine, alkaline phosphatase and alanine aminotransferase concentrations, haemoglobin content, red blood cells, packed cell volume, white blood cells and platelet count.
The occurrence of adverse events during the study was monitored. For any event, the following details were recorded: time it started and stopped, or whether or not it was continuous; course; intensity; suspected relationship to study treatment; and whether or not corrective therapy was given.
Our aim was to recruit at least 480 patients into the study, with approximately 120 patients in each treatment group. This was the number needed in order to detect a 22 % difference between active groups and placebo (90 % power) assuming a "no vomiting" rate of 50 % (based on previous observations of placebo no vomiting rates [6, 7] ).
STATISTICAL ANALYSIS
The chi-square test was used to detect differences between treatment groups for "no vomiting", "no nausea", total control and adverse events. The Cox log rank test was used to detect differences between treatment groups in the survival distributions of the variables: time to less than total control, time to first episode of vomiting, time to first episode of nausea and time to first use of rescue antiemetics over the first 24 h. Pairwise comparisons were made between placebo and each of the granisetron treatment groups using the modified Bonferroni correction to maintain an overall significance level of 5 %. Logistic regression analysis (at a significance level of 10 %) was used to investigate the presence of any treatment-byfactor interaction.
Results
A total of 527 patients (96 % women) were recruited and allocated randomly to receive placebo (n : 133), granisetron 0.1 mg (n : 132), granisetron 1.0 mg (n : 134) or granisetron 3.0 mg (n : 128). There were no significant differences in patient characteristics between the four groups (table 1) .
The groups were comparable in the type of surgery performed, anaesthetic agents and technique used, duration of operation and perioperative use of opioid analgesics (table 2) .
The two larger doses of granisetron (1.0 mg and 3.0 mg) provided effective prophylaxis against vomiting: 63.4 % and 61.7 % of patients, respectively, were free from vomiting in the first 24 h after surgery (P : 0.001 vs placebo), and 78.4 % and 76.6 %, respectively, in the first 6 h (P : 0.001 vs placebo). The results are summarized in table 3.
Significantly more patients did not require rescue antiemetics (prochlorperazine or metoclopramide) in the granisetron 1.0 mg (P : 0.007) and granisetron 3.0 mg (P : 0.003) groups than in the placebo group. Overall, the distribution of survival times to first episode of vomiting, first episode of nausea, less than total control and first use of rescue antiemetic therapy differed significantly (P : 0.01) between the granisetron 1.0 mg and 3.0 mg groups and the placebo group, with the granisetron groups performing better.
There were no significant treatment-by-factor interactions for age, weight, previous history of PONV-motion sickness, menopausal status, duration of anaesthesia or study country (table 4) . Only two significant treatment-by-factor interactions emerged from the analysis: type of surgery and use of opioid analgesics (table 4). In both cases, the treatment groups were well matched for these factors (table 2). Of those patients who did not receive an opioid analgesic, 69.75 % vomited, while only 40 % of those who received an opioid analgesic vomited. There were no differences in patients' assessment of pain in the four groups. In general, no more than 15 % of patients in each group experienced severe pain at any time.
The groups were comparable in time taken after operation to respond to verbal commands and time taken for return of bowel function. Similarly, there were no significant differences between the treatment groups in vital signs during the study or in haematological or biochemical variables. Nine patients had a two-fold elevation in hepatic enzymes after operation. Although this was of some clinical concern to the investigators, the incidence of increased concentrations of hepatic enzymes was well distributed among the four treatment groups. The most common adverse events were constipation, headache and abdominal pain, but there were no significant differences in their occurrence between the treatment groups.
Discussion
This double-blind study was designed to determine the efficacy of three different single doses of i.v. granisetron (0.1 mg, 1.0 mg, and 3.0 mg) compared with placebo in the prevention of PONV in patients undergoing open abdominal surgery or vaginal hysterectomy. Patients recruited into the study were a homogeneous group of mainly women undergoing gynaecological procedures, for whom PONV constitutes a well recognized problem [8] [9] [10] [11] [12] . The groups were well matched for known risk factors, such as sex, age, surgical and anaesthetic procedures, and the use of opioid analgesics. There was a slight imbalance between the groups with respect to history of PONV and motion sickness; this, however, did not affect the results of the study, as demonstrated by the treatment-by-factor analysis.
The results confirmed that PONV is common in these patients undergoing mainly gynaecological surgery, if no prophylactic antiemetic treatment is given, using a standard anaesthetic technique. Prophylactic administration of granisetron 1.0 mg or 3.0 mg resulted in a significant reduction in the numbers of patients who experienced postoperative vomiting during the periods 0-6 h and 0-24 h. The first episode of vomiting also occurred significantly later in the granisetron 1.0 mg and 3.0 mg groups than in the placebo group. Similar significant differences were seen in those patients who experienced no nausea or who achieved total control: doses of 1.0 mg and 3.0 mg were equally effective and both were significantly more effective than placebo. The granisetron 0.1 mg group was not significantly superior to placebo for any of the efficacy variables. Use of rescue medication over the first 24-h period was less common in the granisetron 1.0 mg and 3.0 mg groups (24.6 % and 22.7 % of patients, respectively) than in the placebo group (39.8 % of patients). Also, distribution of survival times to first use of rescue antiemetics differed significantly between the granisetron 1.0 mg and 3.0 mg groups and the placebo group, in favour of granisetron.
The majority of patients in each of the groups received opioid analgesics, but granisetron appeared to be effective whether or not opioids had been given. In either case, the response was most marked in the granisetron 1.0 mg group. The reduction by granisetron in the proportion of patients who vomited was less marked in patients who had received opioids because there was less likelihood of vomiting in these patients (as indicated by the placebo group) despite the known emetogenic potential of opioids. Evidence that effective pain relief can prevent nausea and vomiting may account for this finding [13] .
An important side effect of currently used antiemetics (droperidol, metoclopramide and prochlorperazine) in the perioperative period is sedation, which has the potential for delaying recovery from anaesthesia. None of the three doses of granisetron used in this study caused any delay in recovery from anaesthesia. The study raised no concerns about the safety of granisetron. The safety profiles of the three doses of granisetron used in this study were similar to placebo in terms of adverse events and changes in vital signs, and haematological and biochemical variables. The side effects most commonly encountered were constipation and headache. Although both of these complaints are known to be associated with 5-HT3 receptor antagonists [14] , the incidence and severity of both events were similar to those in the placebo group.
These encouraging results are similar to those obtained with another 5-HT3 receptor antagonist, ondansetron [7, 12, 15] . Moreover, direct comparison of granisetron and a classic antiemetic, the dopamine receptor antagonist, metoclopramide, has clearly demonstrated the superiority of granisetron [16] . Extrapyramidal effects may be a problem with dopamine antagonists and their absence with selective 5-HT3 antagonists is a distinct advantage.
In conclusion, granisetron proved effective in the prevention of PONV. Our data do not suggest that increasing the dose from 1.0 mg to 3.0 mg confers any additional benefit; a dose-response plateau appeared to have been reached. We conclude, therefore, that 1.0 mg is the optimum dose. Further studies are required to compare the efficacy of granisetron with other commonly used antiemetics, and to define its role in patients undergoing different surgical procedures, particularly day surgery.
